-
1 Comment
Neurocrine Biosciences, Inc is currently in a long term uptrend where the price is trading 0.4% above its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.0.
Neurocrine Biosciences, Inc's total revenue rose by 1.6% to $248M since the same quarter in the previous year.
Its net income has increased by 923.2% to $348M since the same quarter in the previous year.
Finally, its free cash flow fell by 15.4% to $84M since the same quarter in the previous year.
Based on the above factors, Neurocrine Biosciences, Inc gets an overall score of 4/5.
| Industry | Drug Manufacturers - Specialty & Generic |
|---|---|
| Exchange | F |
| CurrencyCode | EUR |
| ISIN | US64125C1099 |
| Sector | Healthcare |
| Market Cap | 10B |
|---|---|
| PE Ratio | 32.27 |
| Beta | 0.33 |
| Target Price | 122.19 |
| Dividend Yield | None |
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for NB3.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
